Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck & Co wins another US Fosamax bellwether case

This article was originally published in Scrip

Executive Summary

Merck & Co has picked up another win in a so-called bellwether case where an individual has alleged in a product liability suit that the bisphosphonate Fosamax (alendronate) caused jaw necrosis. Merck has now won three of the first four bellwether cases in the litigation – with the cases generally alleging that Fosamax can cause osteonecrosis of the jaw and that Merck failed to properly warn of the risk.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC010877

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel